by Illana Goldfinger, Life Sciences Practice Group Leader Most discussions surrounding recent changes to vaccine recommendations have focused on public health or healthcare delivery. For life sciences companies and their insurers, however, the more important question is how these developments may reshape risk across multiple lines of coverage. While traditional vaccine product liability remains an… Read More
Life Sciences
Why D&O premiums keep rising in biotech, and what boards can learn from it
By Illana Goldfinger, Life Sciences practice group leader While many brokers lament the “soft market” and excess capacity across most commercial lines, the picture looks quite different in Life Sciences, especially in biotech. D&O premiums continue to climb, and markets willing to take on this class of risk are shrinking. So, what’s driving this trend?… Read More
Staying ahead of Life Sciences risk
Bridge Specialty Group holds market recognition that enables us to connect retail partners with tailored insurance solutions, and we do that through our specific practice groups including Property, Casualty, Environmental, Executive Risk, Farm & Ranch, Healthcare, Life Sciences, Personal Lines, Public Entity, Transportation and Workers’ Compensation. As we continue to expand our products and capabilities… Read More
